马德里——罗氏控股公司表示，预计其正在开发的一款药丸将成为一种晚期肺癌的新标准治疗方案，这也是该公司首次进军肿瘤市场中的一个新兴领域。
MADRID—Roche Holding ROP -0.31%decrease; down pointing triangle said it expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company’s first shot at an emerging field within the oncology market.
这家瑞士制药商正在研发多款针对长期以来难倒业界的癌症驱动因素的药物。美国生物技术公司Revolution Medicines在胰腺癌方面取得的突破让该领域进入投资者视野，而罗氏则计划凭借肺癌药物divarasib切入这一领域。
The Swiss drugmaker is working on several drugs that target a driver of cancers that long eluded the industry. A breakthrough in pancreatic cancer from U.S. biotech Revolution Medicines put the field on investors’ radar, and Roche aims to venture into it with lung-cancer medicine divarasib.